🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are hiring! Work in #biotech in the heart of Kendall Square Association linkedin.com/jobs2/cap/view…

New investor in Fujifilm, additions to Suono Bio #leadership #team, and Xconomy #XconomyAwards all in one day! Busy day! #biotech #BiotechWeekBoston Biotech Week Boston

Very proud of the team for our first publication in J Controlled Release with #artwork by Anna Hupalowska and many thanks to collaborators Giovanni Traverso , #RobertLanger MIT ChemE Dept Koch Institute at MIT and #JoeLennerz, MassGeneral News

New perspective on #zolgensma issue and broader impacts for #biopharma, #drugdevelopment, and #genetherapy DeciBio decibio.com/2019/10/02/zol…

Last year, we launched The Engine’s 1st Tough Tech Summit, convening changemakers igniting the Tough Tech movement. Excited to continue the dialogue @ our 2nd annual Tough Tech Summit (Oct 21-22)! Follow #ToughTech The Engine this week to learn what’s next for Tough Tech.

“In the 3 years since its inception, The Engine has bridged the gap between ‘tough tech’ companies and venture capital with remarkable success.” Great profile by Massachusetts Institute of Technology (MIT) News Zach Winn, interviewing Katie Rae @cambridgecrops Commonwealth Fusion Systems ISEE news.mit.edu/2019/the-engin… #ToughTech

Thrilled to announce our new #partner to advance our portfolio of treatments for #IBD towards the #clinic businesswire.com/news/home/2020…

Very cool program for #healthtech #startups out of UCSF Rosenman Institute offering #funding, #mentorship, and other support. Deadline to apply is July 6. #founders don't delay!! rosenmaninstitute.org/adapt

Phenomenal #toughtech #investors! Suono Bio lucky to have them #biotech

Had the pleasure to speak with Max Finder of Bountiful about #entrepreneurship, #biotech #startups , and what Suono Bio is up to. Have a listen!

Great writeup by Zach Winn Massachusetts Institute of Technology (MIT) on the power of #ultrasound for #drugdelivery and how Suono Bio might enable the use of #nucleicacids and #DNA and #RNA drugs more broadly. #IBD news.mit.edu/2021/suono-bio…

10 out of 10 recommend listening to this podcast of Suono Bio's journey from the lab to the marketplace, an excellent example of how ideas get shaped into impactful #innovations. Listen here apple.co/3iP7G6D Carl Schoellhammer MIT Office of Innovation and Strategy Massachusetts Institute of Technology (MIT)

Official #predictions2022 for the #cellandgenetherapy field. Have a look and let us know what you think will happen #biotech #celltherapy #genetherapy #oligonucleotides decibio.com/insights/2022-…

Making #RNA #medicines more broadly applicable will take new #delivery technologies. Suono Bio 's platform for formulation-agnostic delivery of #oligos may do just that! businesswire.com/news/home/2022…

How to deliver #RNA therapeutics to the GI tract for #Crohns & #IBD? Suono Bio publishes in JPharmSci "This demonstrates our capability to deliver RNAs and siRNAs to gene targets without need for any formulation" says co-founder Carl Schoelhammer Carl Schoellhammer businesswire.com/news/home/2022…

got to chat #siRNA and #oligos with @juneatsirnagen Want to see where the #therapeutics field will go? have a read and find out! #strategyconsulting #therapeutics #genetherapy decibio.com/insights/the-b…

.Suono Bio founded by Carl Schoellhammer announced their first patient dosed with SuonoCalm. Congrats to Suono Bio for leading the first in-human testing of this next technology! Read more: businesswire.com/news/home/2023…

Looking forward to connecting with friends new and old at #ASGCT23

This Giving Tuesday, consider helping baby Lucas! His parents Mama2Lukie and Nathan Guo are working with world class scientists on drug dev for his ultra-rare disease, ZTTK. They have a comprehensive plan to put this money to work to accelerate research: tinyurl.com/4m5xa239

Our CEO, Jason C. Foster, spoke to Carl Schoellhammer (Carl Schoellhammer) from DeciBio to explore the evolution of the #celltherapy sector and how innovative technologies are shaping #PatientAccess to these life changing therapies. Read more: decibio.com/insights/ori-b…